Vivani Medical Inc (VANI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.11+1.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Vivani Medical Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.09
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-0.33
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-0.455

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Release Phase 1 results for NPM-139 by end 2026	It plans Phase 1 results for NPM-139 also by year-end.	Intact	NPM-139 Phase 1 results delayed beyond 2026-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses near -$6.8M in 2026-Q1	Operating losses are improving slightly, from -$7.46M to -$6.82M in early 2026.	Intact	Operating loss worsens beyond -$7.5M in 2026-Q1	Operating income: $-6.874M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$6.8M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 2026-6,874,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 001e8229-2bab-4538-a83a-ae218f7dead1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Release SLIM-1 top-line results by end 2026	Vivani aims to release SLIM-1 results by end of 2026.	Intact	SLIM-1 results delayed beyond 2026-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 0
2026-07-25	Unavailable	Unavailable	2 / 0
2026-07-26	Unavailable	Unavailable	2 / 0
2026-07-27	Unavailable	Unavailable	2 / 0
2026-07-28	Unavailable	Unavailable	2 / 0
2026-07-29	Unavailable	Unavailable	3 / 2
2026-07-30	Unavailable	Unavailable	3 / 2
2026-07-31	Unavailable	Unavailable	3 / 2
2026-08-01	Unavailable	Unavailable	2 / 0
2026-08-02	Unavailable	Unavailable	2 / 0
2026-08-03	Unavailable	Unavailable	3 / 2
2026-08-04	Unavailable	Unavailable	3 / 2
2026-08-05	Unavailable	Unavailable	3 / 2
2026-08-06	Unavailable	Unavailable	3 / 2
2026-08-08	Unavailable	Unavailable	2 / 0
2026-08-09	Unavailable	Unavailable	3 / 2
2026-08-10	Unavailable	Unavailable	3 / 2
2026-08-12	Unavailable	Unavailable	2 / 0
2026-08-13	Unavailable	Unavailable	2 / 0
2026-08-14	Unavailable	Unavailable	2 / 0
2026-08-15	Unavailable	Unavailable	2 / 0
2026-08-16	Unavailable	Unavailable	2 / 0
2026-08-17	Unavailable	Unavailable	2 / 0
2026-08-18	Unavailable	Unavailable	2 / 0
2026-08-19	Unavailable	Unavailable	2 / 0
2026-08-20	Unavailable	Unavailable	2 / 0
2026-08-21	Unavailable	Unavailable	2 / 0
2026-08-22	Unavailable	Unavailable	2 / 0
2026-08-23	Unavailable	Unavailable	2 / 0
2026-08-24	Unavailable	Unavailable	2 / 0
2026-08-25	Unavailable	Unavailable	2 / 0
2026-08-26	Unavailable	Unavailable	2 / 0
2026-08-27	Unavailable	Unavailable	2 / 0
2026-08-28	Unavailable	Unavailable	2 / 0
2026-08-29	Unavailable	Unavailable	2 / 0
2026-08-30	Unavailable	Unavailable	2 / 0
2026-08-31	Unavailable	Unavailable	2 / 0
2026-09-01	Unavailable	Unavailable	2 / 0
2026-09-02	Unavailable	Unavailable	2 / 0
2026-09-03	Unavailable	Unavailable	2 / 0
2026-09-04	Unavailable	Unavailable	2 / 0
2026-09-05	Unavailable	Unavailable	2 / 0
2026-09-06	Unavailable	Unavailable	2 / 0
2026-09-07	Unavailable	Unavailable	2 / 0
2026-09-08	Unavailable	Unavailable	2 / 0
2026-09-09	Unavailable	Unavailable	2 / 0
2026-09-10	Unavailable	Unavailable	2 / 0
2026-09-11	Unavailable	Unavailable	2 / 0
2026-09-12	Unavailable	Unavailable	2 / 0
2026-09-13	Unavailable	Unavailable	2 / 0
2026-09-14	Unavailable	Unavailable	2 / 0
2026-09-15	Unavailable	Unavailable	2 / 0
2026-09-16	Unavailable	Unavailable	2 / 0
2026-09-17	Unavailable	Unavailable	2 / 0
2026-09-18	Unavailable	Unavailable	2 / 0
2026-09-19	Unavailable	Unavailable	2 / 0
2026-09-20	Unavailable	Unavailable	2 / 0
2026-09-21	Unavailable	Unavailable	2 / 0
2026-09-22	Unavailable	Unavailable	2 / 0
2026-09-23	Unavailable	Unavailable	2 / 0
2026-09-24	Unavailable	Unavailable	2 / 0
2026-09-25	Unavailable	Unavailable	2 / 0
2026-09-26	Unavailable	Unavailable	2 / 0
2026-09-27	Unavailable	Unavailable	2 / 0
2026-09-28	Unavailable	Unavailable	2 / 0
2026-09-29	Unavailable	Unavailable	2 / 0
2026-09-30	Unavailable	Unavailable	2 / 0
2026-10-01	Unavailable	Unavailable	2 / 0
2026-10-02	Unavailable	Unavailable	2 / 0
2026-10-03	Unavailable	Unavailable	2 / 0
2026-10-04	Unavailable	Unavailable	2 / 0
2026-10-05	Unavailable	Unavailable	2 / 0
2026-10-06	Unavailable	Unavailable	2 / 0
2026-10-07	Unavailable	Unavailable	2 / 0
2026-10-08	Unavailable	Unavailable	2 / 0
2026-10-09	Unavailable	Unavailable	2 / 0
2026-10-10	Unavailable	Unavailable	2 / 0
2026-10-11	Unavailable	Unavailable	2 / 0
2026-10-12	Unavailable	Unavailable	2 / 0
2026-10-13	Unavailable	Unavailable	2 / 0
2026-10-14	Unavailable	Unavailable	2 / 0
2026-10-15	Unavailable	Unavailable	2 / 0
2026-10-16	Unavailable	Unavailable	2 / 0
2026-10-17	Unavailable	Unavailable	2 / 0
2026-10-18	Unavailable	Unavailable	2 / 0
2026-10-19	Unavailable	Unavailable	2 / 0
2026-10-20	Unavailable	Unavailable	2 / 0
2026-10-21	Unavailable	Unavailable	2 / 0
2026-10-22	Unavailable	Unavailable	2 / 0
2026-10-23	Unavailable	Unavailable	2 / 0
2026-10-24	Unavailable	Unavailable	2 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Release Phase 1 results for NPM-139 by end 2026Direct metric needs a verified mapping
Manage operating losses near -$6.8M in 2026-Q1Operating income: $-6.874M
Release SLIM-1 top-line results by end 2026Direct metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-47.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Vivani Medical Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, loss-making development-stage business, not an established earnings compounder. The thesis is in a watch state: management is progressing on stated milestones, but confidence in the evidence is low and recent performance remains below its industry cohort.

What's priced into Vivani Medical Inc

The evidence describes valuation as expensive, but does not provide a peer comparison or details on what investors expect. Fragility is rated low because the concern is expensive valuation alone, rather than expensive valuation combined with weak fundamentals and a turbulent regime.

What the fundamentals likely do

Near term, quarterly losses remain around $6.4 million to $6.8 million, while cash rose to $20.8 million in 2026-Q2 and is expected to support operations through mid-2027. Management says the SLIM-1 results remain on schedule for November 2026 and has begun a Novo Nordisk evaluation of the NPM-139 implant, but these are development milestones rather than proof of commercial success. A guidance cut, weakening jobs data, or the September litigation filing adds risk; the August earnings report was in line.

What Vivani Medical Inc hinges on

The multi-year thesis hinges first on SLIM-1 results supporting a Phase 2 trial in 2027 and on progress in the Novo Nordisk collaboration. It also depends on managing losses and cash runway, with a guidance cut a clear negative signal. Healthcare-sector strength could provide support, while weaker jobs data could raise recession concerns for cyclical names.